PM vs XXII: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PM and XXII share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PM and XXII exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Philip Morris International is one of the world's largest tobacco and nicotine companies, selling Marlboro and other cigarette brands across roughly 180 markets outside the United States. A 2008 spin-off from Altria split the Marlboro trademark by geography: Altria sells it in the US, while PMI owns it everywhere else. What sets PMI apart today is the scale of its pivot away from combustible cigarettes. Its smoke-free portfolio, led by IQOS heated tobacco, ZYN nicotine pouches (gained through the 2023 Swedish Match acquisition), and VEEV vapes, reached about 43% of net revenues in early 2026 and is available in more than 100 markets. In Q1 2026 IQOS shipment volume grew double digits and surpassed Marlboro to become the company's number one nicotine brand by volume in the markets where it competes.

Full PM guide

22nd Century Group Inc. is a tobacco and plant-biotechnology company best known for VLN, its reduced-nicotine-content combustible cigarette, which is the only such product the FDA has authorized to be marketed with reduced-nicotine claims. The company has been commercializing VLN through retail trials in a growing number of US states (including a 2026 expansion into California under the Pinnacle VLN brand) and advancing additional PMTA submissions and licensing plans, including a 100mm-length product aimed at a larger share of the US cigarette market. It also runs contract-manufacturing of conventional tobacco products and has interests in hemp/cannabis and other plant-science lines, though tobacco is the core. The bull thesis rests heavily on regulation: a long-discussed FDA proposal to mandate very low nicotine levels in cigarettes would, if enacted, position VLN's technology at the center of the market.

Full XXII guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• PM drivers: IQOS heated tobacco leadership; ZYN and the US oral-nicotine pouch push.
• XXII drivers: FDA reduced-nicotine rule as the core catalyst; VLN commercialization and state-by-state expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. For XXII, the risks here are severe and central to the story.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PM if you believe its drivers more; XXII if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PM and XXII guides.

PM. Figures are approximate and tied to the asOf date; verify live numbers before acting. PMI tends to trade at a premium to slower-growing tobacco peers like Altria because IQOS and ZYN give it a real growth angle, so the multiple reflects the transition story as much as current earnings. Analysts favor its faster EPS growth, but that view assumes smoke-free momentum continues and regulation stays manageable.

XXII. All figures are approximate, tied to the asOf date, and must be verified against the latest SEC filings before acting; reverse splits and financings can change the share count and per-share figures dramatically between filings. Because the company is loss-making, price-to-earnings and similar multiples are not meaningful. What matters is cash runway, the pace of dilution, listing compliance, and whether the FDA reduced-nicotine mandate advances. Treat any headline number here as a starting point for your own research, not a precise metric, and recognize this is among the higher-risk names an investor can hold.

Headline figures (approximate, Jul 2026): PM shows revenue (ttm) ~$40 billion, growing high single digits; Q1 2026 net revenues rose about 9% year over year, smoke-free mix / drivers Smoke-free products ~43% of net revenues, led by IQOS heated tobacco and ZYN nicotine pouches; IQOS is now the top nicotine brand by volume in its markets, margins / profitability Strong, staple-like margins; adjusted EPS guided to low-double-digit growth in 2026, faster than most consumer-staples peers, dividend Yield well above the broad market (roughly high-3% range), raised every year since the 2008 spin-off; higher payout ratio than some peers; XXII shows revenue trend Small (roughly the mid-teens of millions of dollars in 2025); quarterly revenue has been modest, in the low single-digit millions, figures approximate and to be verified live, profitability Unprofitable, with continued gross and operating losses; going-concern pressure has been a recurring theme in the company's history, balance sheet Fragile; the company has relied on repeated dilutive equity and warrant financings to fund operations, so cash runway is a live question, verify the latest filing, share structure Repeatedly reverse-split (including 1-for-135 in Dec 2024 plus further splits in 2025 and 2026) to keep the Nasdaq minimum bid price; share count has been reset several times.

PM and XXII are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PM and XXII exposure against your real portfolio. It is not an investment adviser.